HCC is seeking an Investor Relations Analyst to shape and lead our investor relations efforts. If you are passionate about healthcare innovation, results-oriented, and eager to make a substantial impact in investor relations, we invite you to apply and join our dedicated team at Health Catalyst Capital.
Health Catalyst Capital (HCC)
风险投资与私募股权管理人
New York，NY 2,066 位关注者
Investing in the future of healthcare
关于我们
Health Catalyst Capital (HCC) is a private equity firm investing in growth stage healthcare information technology, SaaS and technology-enabled service companies that automate business processes with the help of Artificial Intelligence and related technology.
- 网站
-
https://www.healthcatalystcapital.com
Health Catalyst Capital (HCC)的外部链接
- 所属行业
- 风险投资与私募股权管理人
- 规模
- 11-50 人
- 总部
- New York，NY
- 类型
- 合营企业
- 创立
- 2015
- 领域
- Healthcare、Information Technology、HCIT、Personalized Medicine、Social Impact、Population Health、Clinical Decision Support、Venture Capital、Private Equity、Health Policy、Genomics、Diagnostics、value-based care、Referral Management、Network Management、Interoperability、Pharma Services、Payments、FinTech、InsurTech、artificial intelligence、Natural Language Processing和Machine Learning
地点
-
主要
获取路线
515 Madison Avenue
US，NY，New York，10022
Health Catalyst Capital (HCC)员工
动态
-
HCC is seeking an Investor Relations Analyst to shape and lead our investor relations efforts. If you are passionate about healthcare innovation, results-oriented, and eager to make a substantial impact in investor relations, we invite you to apply and join our dedicated team at Health Catalyst Capital.
-
Today, Click Therapeutics announced meeting the primary endpoint in the ReMMi-D, Reduction in Monthly Migraine Days study, a randomized, double-blind and sham-controlled study evaluating the effectiveness and safety of CT-132, an investigational prescription digital therapeutic for the preventive treatment of migraine. Results from the study are further supported by a bridging study in 110 patients on calcitonin gene-related peptide (CGRP) inhibitors, along with an integrated efficacy analysis of both studies. Click looks forward to advancing CT-132, which previously received FDA Breakthrough Device Designation, through regulatory clearance with the goal of providing a new evidence-based treatment option for patients with episodic migraine. Read the full release: https://lnkd.in/g-8w5P2R
-
-
HCC is pleased to share a summary of our research on AI in Biopharma, where we discuss what’s need to unlock its full potential. In short: clean data and interoperable systems. We seek promising businesses to support in a scale-up and remain optimistic about ways the life sciences industry is harnessing the power of AI to accelerate the research and development of new therapies. Read it here: https://lnkd.in/gFzu798x
HCC
healthcatalystcapital.com